(RTTNews) - Altimmune (ALT) announced the FDA has granted Breakthrough Therapy Designation for pemvidutide, a 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment of patients with metabolic dysfunction-associated steatohepatitis.
Jerry Durso, CEO of Altimmune, said: "With this breakthrough designation and alignment with the FDA on registrational Phase 3 trial parameters, we are laser-focused on strengthening the foundation of Altimmune to advance pemvidutide through late-stage development guided by our commitment to serve patients and create value for our stakeholders."
Shares of Altimmune are up 19.4% to $4.19 in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
